Premarket approval for AMS' (American Medical Systems) UroLume endoprosthesis:
This article was originally published in Clinica
American Medical Systems has received US FDA approval to market its UroLume endoprosthesis, a braided wire mesh stent for treating detrusor-external sphincter dyssynergia (DESD), a urologic condition caused by spinal cord injuries. The UroLume is inserted in the urethra of these patients, who suffer a lack of co-ordination between the bladder and the urinary sphincter, leading to the bladder not being emptied completely. AMS of Minneapolis, Minnesota, had received approval for the UroLume in October 1996 for treating benign urethral stricture disease in men (see Clinica No 129, p 17).
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.